Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexamethasone + dimenhydrinate
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination medication consisting of dexamethasone (a corticosteroid) and dimenhydrinate (an antihistamine). This combination is primarily used for the prevention and treatment of postoperative nausea and vomiting (PONV). Clinical studies have shown that this combination is more effective than dexamethasone combined with ondansetron for preventing PONV in various surgical settings.
02
Targets
GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on dexamethasone + dimenhydrinate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexamethasone + dimenhydrinate.